Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Special delivery: unique drug delivery system receives new US patent

  • In News
  • December 22, 2021
  • Samantha Freidin
Special delivery: unique drug delivery system receives new US patent

Let’s rewind to Year 10 biology- you know that mitochondria is the powerhouse of the cell, chances are you vaguely remember the golgi apparatus but do you remember what an exosome is?

Exosomes, or extracellular vesicles are little packages delivering molecules and enhancing cell-to-cell communication.

Clinical- stage biopharmaceutical company Exopharm (ASX: EX1) is utilising exosomes to deliver transformative medicines. Exosomes can be loaded with different active pharmaceutical ingredients and targeted to different tissue or cell types in the body.

The Company has a pipeline of exosome based drug delivery technologies, playing in a space worth USD $175 billion, growing at a compound annual growth rate of 5%.

Strengthening their IP position, Exopharm has been granted a US patent for their LEAP exosome purification technology as methods and compositions for purification or isolation of microvesicles and exosomes. This patented technology enables large-scale, commercial production of exosomes for clinical applications in the emerging drug delivery field.

Dr. Ian Dixon, founder and CEO of Exopharm said: “This patent is potentially a game-changer for Exopharm. Securing a US patent for an important biotechnology manufacturing technology is a major milestone and adds value to our company. Our LEAP technology has the capability to become the industry standard for exosome medicines, a field which is growing strongly and is attracting big companies.”

Exosomes as a drug delivery system hold promise to solve medical problems in rare diseases and improve population health. The applications in vaccines, gene therapy and cancer therapies are vast and could draw the attention of many different pharmaceutical companies looking to enhance the bioavailability of their products.

“While partnering can deliver early revenue and help make exosome medicines mainstream, the long-term future for Exopharm is in developing our own modern exosome medicines,” said Dr. Ian Dixon.

Chief Commercial Officer and Deputy CEO, Dr. Chris Baldwin also commented on the patent saying: “LEAP is one part of Exopharm;s intellectual property and know-how. We are in discussions with potential partners who can use LEAP to make and commercialise their own exosome medicines for a range of diseases including global contract manufacturing organisations like Showa Denko.”

The technology is now patented in both the US and Russia, with Exopharm pursuing more patents in ten other countries as a critical step towards regulatory approval.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • asx ex1
  • biopharma
  • biotech
  • ex1
  • exopharm
  • exosome
  • ian dixon
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.